Subjects with locally advanced or metastatic solid tumours, including high-grade serious ovarian cancer, are being enrolled ...

BillionToOne, a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announced today that its comprehensive genomic profiling assay Northstar ...

Results from a meta-analysis suggest patients with resectable dMMR/MSI-H gastric cancer can forgo perioperative chemotherapy.

The team is optimizing the cancer genome analysis system to integrate it into CRC diagnosis and tailor treatments based on genetic mutations.

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

Colorectal cancer (CRC), a type of cancer that affects the large intestine and rectum, is one of the leading causes of cancer ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the US Food and Drug ...

Researchers used mutational analysis to identify gene mutations that may drive carcinogenesis in colorectal tumors with high ...

which has potential in tumours with a defect in DNA repair processes known as microsatellite instability (MSI). "Vividion's unique technologies and special expertise will significantly strengthen ...